A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests
University of California, Los Angeles (UCLA), Health SciencesA sharp increase in the price of the gout drug colchicine, the result of an unusual FDA policy, led to lower use and poorer disease control. The findings have implications for other drugs, whose price could be similarly affected by government policies and manufacturer decisions.